Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now

When an FDA advisory committee voted unanimously to recommend Eli Lilly’s Alzheimer’s drug donanemab for regulatory approval this week, the decision solidified another significant milestone in a field that had been deeply stagnant for years.